A carregar...

Will FLT3 Inhibitors Fulfill Their Promise in AML?

PURPOSE OF REVIEW: FLT-3 mutations in Acute Myeloid Leukemia (AML) have been brought from discovery in the early 1990's to clinical targeting in the last ten years. Despite several promising leads in pre-clinical models, no agent has yet been approved for clinical use. Here we will review the d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pratz, Keith W., Luger, Selina M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4142569/
https://ncbi.nlm.nih.gov/pubmed/24468836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!